JWH-210

JWH-210

JWH-210.svg

JWH-210 is a synthetic cannabinoid from the naphthoylindole family. It acts as a potent agonist of the CB1 receptor and CB2 receptor, with a slight preference for the CB2 receptor. JWH-210 is part of the JWH series of synthetic cannabinoids, which were developed by John W. Huffman in the 1990s for research purposes.

Chemical Structure

JWH-210 has the chemical formula C₂₅H₂₅NO. Its structure consists of a naphthalene ring substituted at the 1-position with an ethyl group and at the 4-position with a pentylindole group. The IUPAC name for JWH-210 is (4-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone.

Pharmacology

JWH-210 is a potent agonist of the cannabinoid receptors, particularly the CB1 receptor and CB2 receptor. It has been found to have a higher affinity for the CB2 receptor compared to the CB1 receptor. This selectivity makes it of interest in research related to the endocannabinoid system and potential therapeutic applications.

Legal Status

JWH-210 is classified as a controlled substance in several countries. In the United States, it is listed as a Schedule I substance under the Controlled Substances Act. In the United Kingdom, it is classified as a Class B drug. Other countries, such as Canada and Germany, have also placed JWH-210 under their respective controlled substance regulations.

Research and Applications

JWH-210, like other synthetic cannabinoids, has been used in scientific research to study the endocannabinoid system and the effects of cannabinoid receptor activation. It has also been used in the development of new therapeutic agents targeting cannabinoid receptors. However, due to its potent effects and potential for abuse, its use is strictly regulated.

See Also

• Synthetic cannabinoids
• JWH-018
• CB1 receptor
• CB2 receptor
• John W. Huffman